Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/8/2299 |
| _version_ | 1797557907628228608 |
|---|---|
| author | Takahiro Wakasaki Ryuji Yasumatsu Muneyuki Masuda Toranoshin Takeuchi Tomomi Manako Mioko Matsuo Rina Jiromaru Ryutaro Uchi Noritaka Komune Teppei Noda Takashi Nakagawa |
| author_facet | Takahiro Wakasaki Ryuji Yasumatsu Muneyuki Masuda Toranoshin Takeuchi Tomomi Manako Mioko Matsuo Rina Jiromaru Ryutaro Uchi Noritaka Komune Teppei Noda Takashi Nakagawa |
| author_sort | Takahiro Wakasaki |
| collection | DOAJ |
| description | Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (<i>p</i> = 0.0440, <i>p</i> = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (<i>p</i> = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC. |
| first_indexed | 2024-03-10T17:23:53Z |
| format | Article |
| id | doaj.art-e7170ea6627e4d3881a0930b62df2bec |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T17:23:53Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e7170ea6627e4d3881a0930b62df2bec2023-11-20T10:16:38ZengMDPI AGCancers2072-66942020-08-01128229910.3390/cancers12082299Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaTakahiro Wakasaki0Ryuji Yasumatsu1Muneyuki Masuda2Toranoshin Takeuchi3Tomomi Manako4Mioko Matsuo5Rina Jiromaru6Ryutaro Uchi7Noritaka Komune8Teppei Noda9Takashi Nakagawa10Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Head and Neck Surgery, National Hospital Organization, Kyushu Cancer Center, Fukuoka 812-8582, JapanDepartment of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu 802-8561, JapanDepartment of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu 802-8561, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanRecent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (<i>p</i> = 0.0440, <i>p</i> = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (<i>p</i> = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.https://www.mdpi.com/2072-6694/12/8/2299biomarkerchemotherapyC-reactive proteindistant metastasishead and neck squamous cell carcinomaneutrophil to lymphocyte ratio |
| spellingShingle | Takahiro Wakasaki Ryuji Yasumatsu Muneyuki Masuda Toranoshin Takeuchi Tomomi Manako Mioko Matsuo Rina Jiromaru Ryutaro Uchi Noritaka Komune Teppei Noda Takashi Nakagawa Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Cancers biomarker chemotherapy C-reactive protein distant metastasis head and neck squamous cell carcinoma neutrophil to lymphocyte ratio |
| title | Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| title_full | Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| title_fullStr | Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| title_full_unstemmed | Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| title_short | Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| title_sort | prognostic biomarkers of salvage chemotherapy following nivolumab treatment for recurrent and or metastatic head and neck squamous cell carcinoma |
| topic | biomarker chemotherapy C-reactive protein distant metastasis head and neck squamous cell carcinoma neutrophil to lymphocyte ratio |
| url | https://www.mdpi.com/2072-6694/12/8/2299 |
| work_keys_str_mv | AT takahirowakasaki prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT ryujiyasumatsu prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT muneyukimasuda prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT toranoshintakeuchi prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT tomomimanako prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT miokomatsuo prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT rinajiromaru prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT ryutarouchi prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT noritakakomune prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT teppeinoda prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT takashinakagawa prognosticbiomarkersofsalvagechemotherapyfollowingnivolumabtreatmentforrecurrentandormetastaticheadandnecksquamouscellcarcinoma |